8 results about "Levonorgestrel" patented technology

The present invention relates to levonorgestrel for use in a method for providing contraception in a female subject, comprising continuous intravaginal administration of levonorgestrel of from about 60 µg / day to about 100 µg / day. The invention further relates to levonorgestrel for use in a method for treating endometriosis, endometriosis associated pelvic pain (EAPP) and / or dysmenorrhea comprising continuously administering about 60 µg / day to about 160 µg / day of levonorgestrel. Delivery devices, preferably, intravaginal rings for putting the methods in practice are also envisaged.

The present invention relates to levonorgestrel for use in a method of providing contraception to a female subject comprising a sustained intravaginal administration of levonorgestrel of about 60-100 [mu] g / day. The invention further relates to levonorgestrel for use in a method of treating endometriosis, endometriosis-associated pelvic pain (EAPP) and / or dysmenorrhea, comprising a sustained administration of levonorgestrel of about 60-160 [mu] g / day. Dosing devices, preferably vaginal rings, for carrying out these methods are also contemplated.

The invention relates to the technical field of contraceptives, and discloses a levonorgestrel long-acting slow-release implant and a preparation method thereof, the levonorgestrel long-acting slow-release implant comprises the following components by mass: 10-20 parts of a levonorgestrel bulk drug, 25-35 parts of PCL, 40-50 parts of PLGA, 3-8 parts of a solid dispersant, and 3-8 parts of an injection solvent. According to the invention, a composite structure of a levonorgestrel microcrystalline core with a particle size of 5-20 [mu] m and a PLGA-PCL gradient degradation coating is adopted, and an injection solvent is mixed to form a minimally invasive injection suspension; the preparation method comprises the following steps: preparing microcrystals through anti-solvent precipitation, preparing a gradient coating through fluidized bed coating, and mixing to prepare a suspension, thereby obtaining the levonorgestrel long-acting slow-release implant. After being subjected to hypodermic injection through a 27G narrow needle, the nanomaterial is self-assembled into a 3mm columnar solid, can be completely degraded into CO2 and H2O, and has long-term effectiveness, minimally invasive property, degradability and drug release stability.

The invention discloses a light-response antibacterial gold-silver alloy cluster, and belongs to the crossing field of nanomaterial chemistry and biochemistry. According to the invention, levonorgestrel with good biocompatibility is taken as a protective ligand, and the alloy nano-cluster with excellent fluorescence performance and accurate atomic size is synthesized by a room-temperature volatilization one-pot method. The chemical formula of the nano alloy cluster is C255H330Au7Ag5O25 (abbreviated as Au7Ag5L12), the nano alloy cluster belongs to a hexagonal system, and the space group is a chiral space group P212121. The nano-alloy cluster has a smaller size (-2 nm) and good dispersity; the fluorescent probe has strong green fluorescence at room temperature, the fluorescence quantum yield is 47.9%, and the fluorescent probe has the potential for cell imaging. The nano-alloy cluster material can controllably generate active oxygen through photocatalysis, can efficiently destroy a bacterial membrane to cause bacterial death, and can avoid generation of bacterial drug resistance.

A method for providing progestogen only contraception. The method includes the step of orally administering once a day to a subject desiring contraception a dosage form comprising about 0.125 mg to about 0.145 mg of levonorgestrel (LNG) and at least one pharmaceutically acceptable excipient for a period of at least 23 to 30 days or longer.

The invention belongs to the technical field of medicine preparation, discloses a Jinfeng pill for treating ovary and functional damage thereof and a preparation method, and solves the problems of low extraction rate of cornu cervi pantotrichum polypeptide and easy blistering in concentration in the traditional process. During preparation, fresh cornu cervi pantotrichum is subjected to slicing, freeze-drying and low-temperature crushing and then is subjected to closed self-enzymolysis for several hours with several times of water at a certain temperature, the content of cornu cervi pantotrichum polypeptide in the extract reaches 8%-15% by combining ultrafiltration membrane treatment and segmented concentration, and dissipation of effective components during concentration is avoided. A levonorgestrel-induced rat ovarian injury model verifies that the medicine can restore the estrus cycle, reverse ovarian uterine atrophy, improve the ovarian pathological morphology, regulate the serum hormone level and effectively repair the ovarian function, and an efficient Chinese patent medicine and a preparation scheme are provided for clinic.

This invention discloses a *Serratia marcescens* strain for producing levonorgestrel and its applications, belonging to the field of bioengineering technology. This invention provides a method for producing levonorgestrel using the halophilic archaea MVA pathway in *Serratia marcescens*. The production and yield of levonorgestrel are increased through pathway construction, enhanced soluble expression of levonorgestrel synthase, and knockout of endogenous phospholipase. The engineered *Serratia marcescens* strain for producing levonorgestrel constructed in this invention achieves a yield of 73.4 g·L⁻¹ of levonorgestrel in a 30 L fermenter. ‑1 .

The present invention relates to levonorgestrel used in a method of providing contraception in a female subject, comprising continuous intravaginal administration of approximately 60 μg / day to approximately 100 μg / day of levonorgestrel. Furthermore, the present invention relates to levonorgestrel used in a method of treating endometriosis, endometriosis-associated pelvic pain (EAPP), and / or dysmenorrhea, comprising continuous administration of approximately 60 μg / day to approximately 160 μg / day of levonorgestrel. A delivery device, preferably an intravaginal ring, for carrying out these methods is also envisioned.